Quick Facts
Plain-English Summary
The Selank + Semax Blend combines two heptapeptides developed at the Institute of Molecular Genetics of the Russian Academy of Sciences. Both compounds carry regulatory approval in Russia and possess independently published clinical and preclinical evidence bases. Their combination is sold commercially on the premise that anxiety reduction (Selank) and cognitive enhancement (Semax) operate through complementary mechanisms, producing an additive or synergistic nootropic effect. This rationale is mechanistically coherent, but the combination itself has no published pharmacological or clinical research as of 2026.
Selank (Thr-Lys-Pro-Arg-Pro-Gly-Pro) is a stabilised synthetic analogue of tuftsin, an endogenous tetrapeptide with immunomodulatory properties. It was registered by the Russian Ministry of Health as an anxiolytic indicated for generalised anxiety disorder and neurasthenia. Its primary documented mechanisms are GABA-A receptor potentiation and BDNF upregulation in hippocampal tissue. Unlike classical benzodiazepines, it does not appear to produce physical dependence or receptor downregulation in published animal studies.
Semax (Met-Glu-His-Phe-Pro-Gly-Pro) is a synthetic heptapeptide analogue of the ACTH(4-7) core sequence, extended with a Pro-Gly-Pro C-terminus for metabolic stability. It is registered in Russia for ischaemic stroke, transient ischaemic attack (TIA), and cognitive impairment. Its principal mechanisms are melanocortin receptor activation, BDNF upregulation, and VEGF-mediated cerebrovascular support. Russian-language clinical trials report cognitive improvements in stroke populations and attentional enhancement in healthy subjects.
No published study — preclinical or clinical — has examined the pharmacokinetics, pharmacodynamics, safety, or efficacy of the Selank + Semax combination. Evidence for the individual compounds cannot be extrapolated to the blend. Drug-drug interactions in nasal tissue and downstream CNS signalling remain uncharacterised.
The majority of published research on both compounds originates from Soviet-era and post-Soviet Russian institutions and has been subject to limited independent international replication. English-language peer-reviewed literature is sparse, and Western regulatory agencies have not formally assessed either compound.
Mechanism of Action
Proposed mechanisms below are derived from in vitro and rodent studies only. No mechanistic pathway has been validated in a controlled human study.
All mechanistic data is derived from in vitro or rodent studies. Applicability of these pathways in humans is not established.
Animal Data
| Model | Finding | ICPS Status |
|---|
No finding from this section has been replicated in a controlled human trial. Animal-to-human translation for peptides is uncertain and cannot be assumed.
Human Trials
| Trial | Population | Status | ICPS Status |
|---|
Selank + Semax Blend has no FDA, EMA, or Health Canada–approved indications and no published Phase III trial data for any condition as of 2026.
Safety & Side Effects
Selank is generally well-tolerated in published Russian trials. No significant adverse events reported at registered doses. No evidence of physical dependence, receptor downregulation, or withdrawal in animal studies. Long-term safety in humans is not characterised.
Semax is reported as well-tolerated across published stroke and cognitive trials. Most common adverse events are local nasal irritation and transient headache. No serious adverse events reported in the available literature at therapeutic doses.
- Nasal irritation at administration site
- Transient headache, especially at initiation
- Mild mood elevation or emotional blunting (variable)
- Occasional fatigue after dose wears off
- No pharmacovigilance database exists for the blend
- No combination interaction study has been published
- Dual BDNF upregulation — clinical significance unknown
- Nasal absorption pharmacokinetics not characterised for co-administration
- Avoid if pregnant, breastfeeding, or immunocompromised
- No data in children or adolescents
Selank + Semax Blend is not approved by the FDA, EMA, or Health Canada for any medical indication. It is classified as a research compound and is not legal for human therapeutic use in most jurisdictions. Procurement and use outside of registered clinical trials carries regulatory and unknown health risks.
References
Research disclaimer. CompoundProfile publishes summaries of available scientific literature for educational purposes only. This page does not constitute medical advice and should not be interpreted as an endorsement of Selank + Semax Blend for any therapeutic use. Consult a licensed healthcare professional before considering any research compound. All evidence gradings reflect the state of published literature as of August 2026 and are assessed independently by ICPS.
Community Commentary
Selected discussion from r/Peptides · Curated for signal, not volume